Actionable Results
A targeted set of 17 genes and 59 exons that are key in diagnosis, prognosis, and approved therapeutic options in solid adult tumors.
Gene fusions are the result of other genomic events, such as translocation, interstitial deletion, or chromosomal inversion. Gene fusions are known to be driver mutations in many different tumors and more recently, have emerged as therapeutic targets.
While relatively rare, for example ALK rearrangements have been reported as occurring in only 3–8% of non-small lung cell cases, the emergence of targeted gene fusion therapies have made the assessment of these events in tumors extremely important.
While single gene testing methods remain the standard, multigene NGS assays provide an alternative single assay approach to gene fusion detection that conserves often difficult to obtain tissue samples.
